Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Prostate
Descriptor: Met expression


Reference Number: 120
Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147, 386-96 (1995).
PubMed link      E-mail link

Reference Number: 121
Knudsen, B. S. et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60, 1113-7 (2002).
PubMed link      E-mail link

Reference Number: 122
Pisters, L. L. et al. c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154, 293-8. (1995).
PubMed link      E-mail link

Reference Number: 123
Tsuka, H. et al. Expression of c-MET/HGF receptor mRNA and protein in human non-malignant and malignant prostate tissues. Int J Oncol 13, 927-34 (1998).
PubMed link      E-mail link

Reference Number: 248
Nakashiro K, Hayashi Y, Oyasu R. Immunohistochemical expression of hepatocyte growth factor and c-Met/HGF receptor in benign and malignant human prostate tissue. Oncol Rep 10:1149-53 (2003).
PubMed link      E-mail link

Reference Number: 249
van Leenders G, van Balken B, Aalders T, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Intermediate cells in normal and malignant prostate epithelium express c-MET: implications for prostate cancer invasion. Prostate 51:98-107 (2002).
PubMed link      E-mail link

Reference Number: 284
Strohmeyer D, Strauss F, Rossing C, Roberts C, Kaufmann O, Bartsch G, Effert P. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24, 1797-804 (2004)
PubMed link      E-mail link

Reference Number: 326
Zhang YW, Su Y, Lanning N, Gustafson M, Shinomiya N, Zhao P, Cao B, Tsarfaty G, Wang LM, Hay R, Vande Woude GF Enhanced growth of human met-expressing xenografts in a new strain of immunocompromised mice transgenic for human hepatocyte growth factor/scatter factor. Oncogene 24, 101-6 (2005)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 376
Hurle RA, Davies G, Parr C, Mason MD, Jenkins SA, Kynaston HG, Jiang WG. Hepatocyte growth factor/scatter factor and prostate cancer: a review. Histol Histopathol. 20, 1339-49 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 538
Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res. 67, 967-75 2007
PubMed link      E-mail link

Reference Number: 731
Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Woude GV, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 17, 57-67 (2009)
PubMed link      E-mail link

Reference Number: 914
Coleman DT, Bigelow R, Cardelli JA. Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradation. Mol Cancer Ther. 8, 214-24 (2009)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 936
Tu WH, Zhu C, Clark C, Christensen JG, Sun Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer. 10, 556 (2010)
PubMed link      E-mail link

Reference Number: 1010
Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 60, 1113-7 (2002)
PubMed link      E-mail link

Reference Number: 1014
Hay RV, Cao B, Skinner RS, Wang LM, Su Y, Resau JH, Knudsen BS, Gustafson MF, Koo HM, Woude GF, Gross MD. Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. Clin Cancer Res. 9, 3839S-44S (2003)
PubMed link      E-mail link

Reference Number: 1146
Colombel M, Eaton CL, Hamdy F, Ricci E, van der Pluijm G, Cecchini M, Mege-Lechevallier F, Clezardin P, Thalmann G. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate. 72, 713-20 (2012)
PubMed link      E-mail link

Reference Number: 1172
Hu P, Chu GC, Zhu G, Yang H, Luthringer D, Prins G, Habib F, Wang Y, Wang R, Chung LW, Zhau HE. Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One. 6, e28670 (2011)
PubMed link      E-mail link

Reference Number: 1197
Hwang CI, Choi J, Zhou Z, Flesken-Nikitin A, Tarakhovsky A, Nikitin AY. MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF. Cell Cycle. 10, 3834-40 (2011)
PubMed link      E-mail link

Reference Number: 1246
Virtakoivu R, Pellinen T, Rantala JK, Perälä M, Ivaska J. Distinct roles of AKT isoforms in regulating ß1-integrin activity, migration, and invasion in prostate cancer. Mol Biol Cell. 23, 3357-69 (2012)
PubMed link      E-mail link

Reference Number: 1271
Yu H, Li X, Sun S, Gao X, Zhou D. c-Met inhibitor SU11274 enhances the response of the prostate cancer cell line DU145 to ionizing radiation. Biochem Biophys Res Commun. 427, 659-65 (2012)
PubMed link      E-mail link

Reference Number: 1285
Yoshioka T, Otero J, Chen Y, Kim YM, Koutcher JA, Satagopan J, Reuter V, Carver B, de Stanchina E, Enomoto K, Greenberg NM, Scardino PT, Scher HI, Sawyers CL, Giancotti FG. ß4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 123, 682-99 (2013)
PubMed link      E-mail link

Reference Number: 1362
Hagman Z1, Haflidadottir BS, Ansari M, Persson M, Bjartell A, Edsjö A, Ceder Y. The tumour suppressor miR-34c targets MET in prostate cancer cells. Br J Cancer. 109, 1271-8 (2013)
PubMed link      E-mail link

Reference Number: 1442
Ricci E1, Mattei E, Dumontet C, Eaton CL, Hamdy F, van der Pluije G, Cecchini M, Thalmann G, Clezardin P, Colombel M. Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. Prostate. 73, 1738-46 (2013)
PubMed link      E-mail link

Reference Number: 1463
Liu T1, Mendes DE, Berkman CE. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int J Oncol. 43, 1125-30 (2013)
PubMed link      E-mail link

Reference Number: 1516
Hu P1, Chung LW, Berel D, Frierson HF, Yang H, Liu C, Wang R, Li Q, Rogatko A, Zhau HE. Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. PLoS One. 8, e73081 (2013)
PubMed link      E-mail link

Reference Number: 1580
Steffan JJ, Dykes SS, Coleman DT, Adams LK, Rogers D, Carroll JL, Williams BJ, Cardelli JA. Supporting a role for the GTPase Rab7 in prostate cancer progression. PLoS One. 9, e87882 (2014)
PubMed link      E-mail link

Reference Number: 1597
Ding L, Zhang Z, Liang G, Yao Z, Wu H, Wang B, Zhang J, Tariq M, Ying M, Yang B SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells. Cancer Lett. 356(2 Pt B), 828-36 (2015)
PubMed link      E-mail link

Reference Number: 1621
Cheng CY, Hwang CI, Corney DC, Flesken-Nikitin A, Jiang L, Oner GM, Munroe RJ, Schimenti JC, Hermeking H, Nikitin AY. miR-34 cooperates with p53 in suppression of prostate cancer by joint regulation of stem cell compartment. Cell Rep. 6, 1000-7 (2014)
PubMed link      E-mail link

Reference Number: 1719
Wanjala J, Taylor BS, Chapinski C, Hieronymus H, Wongvipat J, Chen Y, Nanjangud GJ, Schultz N, Xie Y, Liu S, Lu W, Yang Q, Sander C, Chen Z, Sawyers CL, Carver BS Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Mol Cancer Ther. 14, 278-88 (2015)
PubMed link      E-mail link

Reference Number: 1786
Li Q, Li Q, Nuccio J, Liu C, Duan P, Wang R, Jones LW, Chung LW, Zhau HE. Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients. Prostate. 75, 1312-21 (2015)
PubMed link      E-mail link

Reference Number: 1882
Mukai S, Yorita K, Yamasaki K, Nagai T, Kamibeppu T, Sugie S, Kida K, Onizuka C, Tsukino H, Kamimura T, Kamoto T, Kataoka H. Expression of human kallikrein 1-related peptidase 4 (KLK4) and MET phosphorylation in prostate cancer tissue: immunohistochemical analysis. Hum Cell. 28, 133-42 (2015)
PubMed link      E-mail link